Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.

Background: The bone-targeting agent zoledronic acid (ZOL) increases breast cancer survival in subsets of patients, but the underlying reasons for this protective effect are unknown. ZOL modulates the activity of osteoclasts and osteoblasts, which form hematopoietic stem cell niches, and therefore m...

Descripción completa

Detalles Bibliográficos

Publicado en:	Breast Cancer Research Vol. 19; pp. 1 - 16
Autores principales:	Ubellacker, Jessalyn M., Haider, Marie-Therese, DeCristo, Molly J., Allocca, Gloria, Brown, Nicola J., Silver, Daniel P., Holen, Ingunn, McAllister, Sandra S.
Formato:	pictorial research tables/charts Journal Article
Publicado:	BioMed Central 3/6/2017
Acceso en línea:	Ver este registro en EBSCOhost